Smith & Nephew plc’s Outperform Rating Reaffirmed at BNP Paribas (SN)
Smith & Nephew plc (LON:SN)‘s stock had its “outperform” rating reissued by research analysts at BNP Paribas in a report released on Friday. They currently have a GBX 1,250 ($20.74) target price on the stock. BNP Paribas’ target price suggests a potential upside of 18.60% from the stock’s previous close.
SN has been the subject of a number of other recent research reports. Analysts at Jefferies Group downgraded shares of Smith & Nephew plc to a “hold” rating in a research note on Tuesday. They now have a GBX 1,000 ($16.59) price target on the stock. Separately, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday. They now have a GBX 1,000 ($16.59) price target on the stock. Finally, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Thursday, August 28th. They now have a GBX 1,230 ($20.41) price target on the stock. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of GBX 987.41 ($16.39).
Shares of Smith & Nephew plc (LON:SN) opened at 1057.00 on Friday. Smith & Nephew plc has a 1-year low of GBX 737.50 and a 1-year high of GBX 1136.00. The stock’s 50-day moving average is GBX 1040.93 and its 200-day moving average is GBX 982.. The company’s market cap is £9.450 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.